Pfizer Pipeline – Our Medicines in Development
Our pipeline of new medicines in development is one of the largest in the pharmaceutical industry, focusing on a broad range of unmet medical needs. Pfizer historically has invested more than $7 billion annually in the research and development of new products across more therapeutic areas than any other company in our industry. Relying on the strength of our pipeline and scientific talent, Pfizer has generated a steady stream of breakthroughs over the years. And now, with our recent acquisition of Wyeth Pharmaceuticals, we have broadened our pipeline to include more promising treatment opportunities in areas such as small molecules, vaccines, and biopharmaceuticals. Our researchers continue to work around the clock and around the globe to ensure the best medicines for our patients in the years to come.
Read Pfizer's commitment to conducting ethical research, ensuring the safety and privacy of patients and how we approach clinical trials.
Learn about the four phases of clinical trials and the importance of each in ensuring the safety and effectiveness of medical treatments.
- Contact Us
- Investors
- Sitemap
- Careers
- Business to Business
- Terms of Use
- Global Network
- Privacy Policy
Copyright © 2002–2010 Pfizer Inc. All rights reserved. This information is intended only for residents of the United States. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Pfizer Inc is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.
